Acurx Pharmaceuticals (ACXP) Share-based Compensation (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Share-based Compensation came in at $685054.0 in Q1 2026, up 105.35% YoY from $333598.0 in Q1 2025, and up 132.38% on a QoQ basis from $294794.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Share-based Compensation (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Share-based Compensation data on file, last reported at $685054.0 in Q1 2026.
- Quarterly Share-based Compensation rose 105.35% year-over-year to $685054.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $685054.0 (down 15.14% YoY) and the FY2025 annual result came in at $1.2 million, down 52.06% from the prior year.
- Share-based Compensation improved to $685054.0 in Q1 2026, from $294794.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $894523.0 in Q1 2024 to a low of $1793.0 in Q2 2025.
- A 5-year average of $356370.5 and a median of $294794.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 99.0% — and 2025, when it soared 869.46%.
- Tracing ACXP's Share-based Compensation over 5 years: stood at $696965.0 in 2022, then grew by 19.56% to $833285.0 in 2023, then sank by 58.57% to $345191.0 in 2024, then fell by 14.6% to $294794.0 in 2025, then jumped by 132.38% to $685054.0 in 2026.
- The last three Share-based Compensation figures came in at $685054.0 (Q1 2026), $294794.0 (Q4 2025), and $183713.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 719,063.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 719,063.00 |
| Jun 30, 2026 | 719,063.00 |
| Mar 31, 2026 | 685,054.00 |
| Mar 31, 2026 | 685,054.00 |
| Dec 31, 2025 | 294,794.00 |
| Dec 31, 2025 | 294,794.00 |
| Sep 30, 2025 | 183,713.00 |
| Sep 30, 2025 | 183,713.00 |
| Jun 30, 2025 | 1,793.00 |
| Jun 30, 2025 | 1,793.00 |
| Mar 31, 2025 | 333,598.00 |
| Mar 31, 2025 | 333,598.00 |
| Dec 31, 2024 | 345,191.00 |
| Dec 31, 2024 | 345,191.00 |
| Sep 30, 2024 | 18,950.00 |
| Sep 30, 2024 | 18,950.00 |
| Jun 30, 2024 | 109,521.00 |
| Jun 30, 2024 | 109,521.00 |
| Mar 31, 2024 | 894,523.00 |
| Mar 31, 2024 | 894,523.00 |